Highest-materiality recent filing
ALX Oncology Q2 2026 net loss $18.0M; cash $153.4M; refinances debt facility
GAAP net loss of $18.0M ($0.13/share) vs $25.9M ($0.49/share) in Q2 2025; non-GAAP net loss $14.3M.
Co-founder Corey Goodman resigned as Chairman and board member effective June 29, 2026, for personal reasons.
ALX Oncology enters $50M loan facility with HSBC; $10M drawn at close, refinances existing debt
Total facility up to $50M: $10M drawn at closing to refinance Oxford Finance/SVB loans; $20M available to June 30, 2028.
Vote results: Daniel Curran (100.9M for), Rekha Hemrajani (82.7M for), Chris Takimoto (100.9M for) elected to Class II board.
ALX Oncology Q1 2026 net loss narrows to $17.9M; evorpacept data shows durable responses
GAAP net loss of $17.9M ($0.17/sh) vs $30.8M ($0.58/sh) YoY; R&D expenses down to $13.6M.
ALX Oncology appoints Jeff Knight as Chief Development and Operating Officer
Jeff Knight, former CDOO at Crinetics, appointed effective April 13, 2026; role includes clinical development and operations.
ALX Oncology Q4 GAAP net loss $22.8M ($0.42/sh), completes $150M offering, cash runway to 1H 2028
Cash $48.3M at Dec 31, 2025; after Feb 2026 $150M offering net $140.4M, runway through 1H 2028.
ALX reports $48.3M cash; CD47 predictive of evorpacept response in HER2+ breast cancer Phase 1b/2
Preliminary cash, cash equivalents, and investments total $48.3M as of Dec 31, 2025.
ALX Oncology prices ~$150M equity offering at $1.57/share; includes pre-funded warrants
Gross proceeds expected ~$150M from sale of 76,979,112 common shares at $1.57 and pre-funded warrants for 18,574,120 shares at $1.569.
ALX Oncology increases inducement plan share reserve by 1.3M shares to total 2.8M shares
Board amended 2025 Inducement Equity Incentive Plan to reserve an additional 1,300,000 shares of common stock.
GAAP net loss for Q3 2025 was $22.1M ($0.41/share), improved from $30.7M ($0.58/share) in Q3 2024.
Alan Sandler resigns as CMO effective Sep 26, 2025, returns to Board as director.
GAAP net loss of $25.9M ($0.49/share) vs $39.4M ($0.76) in Q2 2024; R&D expense down 48% to $18.0M.
ALX Oncology stockholders elect directors, approve advisory pay vote, ratify KPMG
Scott Garland (23.6M for) and Barbara Klencke (30.8M for) elected as Class II directors to serve until 2028 annual meeting.
ALX Oncology Reports Q1 2025 Financial Results, Updates on Evorpacept and ALX2004 Pipeline
Reported Q1 2025 net loss of $30.8M ($0.58 per share) compared to $35.6M in Q1 2024; cash runway extended into Q4 2026 with $107.0M in cash.
ALX Oncology receives Nasdaq bid price non-compliance notice; 180-day cure until Oct 20, 2025
Nasdaq notified ALXO on Apr 23, 2025 that its common stock failed to maintain $1.00 minimum bid price for 30 consecutive business days.
ALX Oncology Q4 net loss $29.2M; cash $131.3M; evorpacept data positive; workforce cut
GAAP net loss Q4 2024: ($29.2M) or ($0.55)/share, improved from ($45.5M) or ($0.93)/share in Q4 2023.
ALX Oncology reduces workforce by 30%; President and CSO Pons to depart April 2025
Board approved ~30% workforce reduction to prioritize pipeline and extend cash runway; substantially complete by May 2025.
ALX Oncology appoints Harish Shantharam as CFO and adds Klencke, Takimoto to board
Harish Shantharam named CFO effective Jan 21, 2025; base salary $490k, target bonus 40%, option for 600k shares.
ALX Oncology adopts 2025 Inducement Plan, reserves 1.5M shares for new-hire equity awards
Board approved Inducement Plan on Jan 16, 2025; effective immediately.
ALX Oncology appoints Alan Sandler as CMO; CFO Garcia departs with separation agreement
Alan Sandler, M.D., appointed Chief Medical Officer effective Nov 10, 2024; base salary $575k, signing bonus $50k, 700k stock options.
ALX Oncology reports Q3 net loss $0.58/share; CFO Garcia resigns, Pinto interim
GAAP net loss $30.7M ($0.58 per share) vs $51.0M ($1.24) in Q3 2023; non-GAAP net loss $23.7M.
ALX Oncology CMO Sophia Randolph resigns; separation includes $503,880 and accelerated vesting
CMO Sophia Randolph resigns effective Oct 11, 2024; she leaves to pursue other professional opportunities.
ALX Oncology reports Q2 net loss $39.4M; ASPEN-06 gastric cancer data shows ORR 40.3% vs 26.6%
GAAP net loss $39.4M ($0.76/sh) vs $34.2M ($0.84/sh) in Q2 2023; non-GAAP net loss $32.1M.
ALX Oncology appoints Alan Sandler to Board; Pons and Randolph resign from Board
Alan Sandler, M.D., appointed to Board effective Aug 5, 2024; receives initial option for 40,400 shares vesting over 36 months.
ALX Oncology annual meeting results: all three director nominees elected, proposals approved
Corey Goodman, Jason Lettmann, Sophia Randolph elected as Class I directors for terms until 2027.
ALX Oncology Q1 net loss widens to $35.6M; evorpacept B-NHL data shows 83% CRR
GAAP net loss $35.6M ($0.71/sh) vs $30.2M ($0.74/sh) in Q1 2023; non-GAAP loss $28.5M vs $23.8M.
ALX Oncology loses two directors; board drops below majority independent; cure period triggered
Jack Nielsen resigned April 28 for health; Itziar Canamasas resigned April 30 due to new professional role.
ALX Oncology Q4 2023 net loss $45.5M; cash $218.1M; ASPEN-06 interim ORR 52%
GAAP net loss Q4 2023: $45.5M ($0.93/share); FY 2023 net loss $160.8M ($3.74/share).
ALX Oncology amends loan agreement; extends draw period to June 30, 2024 and adds ASPEN-06 milestone
Term A Loan draw period extended from Dec 31, 2023 to June 30, 2024.
ALX Oncology Q3 net loss $51.0M; positive Phase 2 gastric cancer data; CEO change
Q3 2023 GAAP net loss $51.0M ($1.24/diluted share) vs $35.3M ($0.87) in Q3 2022.
ALX Oncology prices $55M public offering of common stock and pre-funded warrants
Priced public offering of 7,370,690 shares at $6.38/share and pre-funded warrants for 1,250,000 shares at $6.379/warrant.
ALX Oncology reports positive interim Phase 2 ASPEN-06 data for evorpacept in HER2+ gastric cancer
Confirmed ORR 52% for evorpacept combo vs 22% control; median DOR not reached vs 7.4 months.
ALX Oncology reports preliminary Q3 2023 cash position of $196.5M
Preliminary cash, cash equivalents, and investments of $196.5M as of Sep 30, 2023, subject to quarter-end close.
ALX Oncology appoints Jason Lettmann as CEO; Jaume Pons becomes CSO
Jason Lettmann named CEO effective Sept 6, 2023; succeeds Jaume Pons who becomes President and CSO.
ALX Oncology Q2 net loss $34.2M; terminates MDS/AML programs, delays ALTA-002 IND
GAAP net loss $34.2M ($0.84/share); non-GAAP net loss $27.9M vs $27.1M prior year.
ALX Oncology amends bylaws and announces annual meeting voting results
Board approved amended bylaws effective June 17, 2023, enhancing stockholder nomination procedures and complying with universal proxy rules and Delaware law.
ALX Oncology Q1 net loss $30.2M ($0.74/sh); cash $256.2M; evorpacept trials advance
GAAP net loss $30.2M vs $24.5M YoY; non-GAAP net loss $23.8M vs $19.0M.
ALX Oncology says SVB exposure immaterial; loan facility with SVB under review
Uninsured cash at SVB is less than 0.8% of total cash equivalents and investments.
ALX Oncology reports Q4 net loss $30.7M; cash $282.9M; clinical milestones ahead
Q4 2022 GAAP net loss $30.7M ($0.75/sh) vs $28.4M ($0.70/sh) in Q4 2021.
ALX Oncology appoints Scott Garland to Board of Directors effective Nov 28, 2022
Appointed Scott Garland to Board of Directors effective November 28, 2022; Board size increased from 7 to 8.
GAAP net loss $35.3M ($0.87/diluted share) vs $24.6M ($0.61) in Q3 2021; non-GAAP loss $29.1M vs $20.4M.
Initial draw of $10M from first $50M tranche; remaining $40M available through end of 2023.
ALX Oncology Q2 net loss $32.9M ($0.81 EPS); FDA fast track and ODD for evorpacept
Net loss GAAP $32.9M ($0.81/share) vs $16.3M ($0.40) in Q2 2021; R&D spend $26.7M vs $11.2M.
ALX Oncology annual meeting results: two directors re-elected, Say-on-Pay approved, KPMG ratified
Itziar Canamasas and Jack Nielsen reelected as Class II directors with 31,224,326 and 27,509,300 votes for respectively.
ALX Oncology Reports Q1 2022 Financial Results, Provides Clinical Updates for Evorpacept
First patient dosed in Phase 2/3 ASPEN-06 study evaluating evorpacept in HER2-positive gastric/GEJ cancer.
ALX Oncology appoints Dr. Itziar Canamasas to Board of Directors, effective April 11, 2022
Board size increased from six to seven directors; Canamasas appointed as Class II director with term expiring at 2022 Annual Meeting.
ALX Oncology reports Q4 2021 net loss $28.4M ($0.70/shr); cash $363.7M through mid-2024
GAAP net loss Q4 2021: $28.4M ($0.70/shr) vs $18.8M ($0.50/shr) year ago; full year loss $83.5M ($2.07/shr).
ALX Oncology enters $150M at-the-market stock offering agreement
Entered Sales Agreement with Cantor Fitzgerald and Credit Suisse for ATM offering of up to $150M in common stock.
ALX Oncology Q3 net loss $24.6M; cash $385M; acquired ScalmiBio
GAAP net loss $24.6M ($0.61/sh) vs $10.8M ($0.36/sh) in Q3 2020; non-GAAP loss $20.4M.
the Company’s President and Chief Scientific Officer position will be eliminated effective in April 2025
Effective January 18, 2025, the Board appointed Barbara Klencke, M.D. to serve as a Class II director of the Board
Ms. Pinto resigned as the interim Chief Financial Officer effective as of the same date and will remain the Company’s Senior Vice President, Finance and Chief Accounting Officer and the principal accounting officer.
and Chris Takimoto, M.D., Ph.D., F.A.C.P., to serve as a Class III director of the Board
Effective January 21, 2025, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Harish Shantharam to the office of Chief Financial Officer
Effective on the same date, Dr. Sandler resigned as a member of the Board and all committees thereof.
As previously disclosed, Peter Garcia resigned as Chief Financial Officer of the Company effective November 8, 2024, due to personal reasons.
On November 10, 2024, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Alan Sandler, M.D., age 68, to the office of Chief Medical Officer to fill a recently created vacancy.
On November 5, 2024, Peter Garcia, Chief Financial Officer of the Company informed the Company of his resignation from his position effective November 8, 2024, due to personal reasons.
On November 7, 2024, the Board of Directors (the “Board”) of the Company appointed Shelly Pinto, the Company’s Senior Vice President, Finance and Chief Accounting Officer, as the Company’s interim Chief Financial Officer, effective upon Mr. Garcia’s resignation.
On September 30, 2024, Sophia Randolph, M.D., Ph.D., Chief Medical Officer of ALX Oncology Holdings Inc. (the “Company”) informed the Company of her resignation from her position effective October 11, 2024, to pursue other professional opportunities.
In addition, on August 5, 2024, Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., resigned as members of the Company’s Board.
Max materiality 0.85 · Median 0.62 · Most common event earnings